Caricamento...
Phase 2 Study of Carboplatin, Docetaxel, and Bevacizumab as Frontline Treatment for Advanced Nonsmall-Cell Lung Cancer
BACKGROUND: Bevacizumab has recently been demonstrated to prolong overall survival when added to carboplatin and paclitaxel for chemotherapy-naïve patients with nonsquamous nonsmall-cell lung cancer (NSCLC). However, the effects of combining bevacizumab with other standard, front-line, platinum-base...
Salvato in:
| Pubblicato in: | Cancer |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2010
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5145307/ https://ncbi.nlm.nih.gov/pubmed/20225327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24996 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|